546 results about "Total cholesterol" patented technology

The present invention is directed to methods of reducing plasma triglyceride level in subjects by administering docosahexaenoic acid (DHA). The method can comprise administering daily to the subject a dosage form comprising docosahexaenoic acid ester substantially free of eicosapentaenoic acid (EPA), wherein the DHA is derived from an algal source. In some embodiments, the method comprises administering daily to the subject a dosage form comprising DHA ester substantially free of EPA, wherein the DHA ester is about 60% to about 99.5% (w / w) of the total fatty acid content of the dosage form. In some embodiments, the method comprises administering daily to the subject a dosage form comprising about 200 mg to about 4 g of DHA ester substantially free of EPA. In some embodiments, the foregoing methods also result in a lowering of the amount of total cholesterol in the subject.

A composition is provided containing at least 90% of policosanols obtained from rice bran wax, wherein the policosanols contain from about 25 to about 35% of octacosanol, and its use in providing significant improvements in total cholesterol and / or LDL reduction in subjects in need thereof.

The invention relates to the technical field of microorganism, and discloses a Lactobacillus reuteri and its application. The preservation number of the Lactobacillus reuteri CCFM8631 is CGMCC No.14394; the level of mice peripheral neurotransmitter 5-hydroxytryptamine can be significantlyimproved; the rise of the mice peripheral blood testonsterone level and the abundant abnormity of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora by high glucose and high fatty diets are recovered; the tolerated simulative gastrointestinal fluid is rapidly planted in an intestinal tract, so as to significantly improve the pathological injury of metabolic syndrome mice liver and duodenum and rise of triglyceride and total cholesterol content in the serum by high glucose and high fatty diets are significantly improved; the Lactobacillus reuteri can be used for preventing, delaying or treating metabolic disorder such as metabolic syndrome, irritable bowel syndrome, and anxiety, depression and other metal diseases related to irritable bowel syndrome.

The invention relates to the technical field of microorganisms, and discloses bifidobacterium adolescentis and an application thereof. The collection number of the bifidobacterium adolescentis CCFM8630 is CGMCC No.14395. The bifidobacterium adolescentis CCFM8630 has the advantages that the level of neurotransmitter 5-hydroxytryptamine in peripheral blood of rats can be remarkably upgraded by the bifidobacterium adolescentis CCFM8630; the increased level of hormones such as testosterone in the peripheral blood of the rats due to high-glucose and high-fat diet and anomaly of abundance of Blautiaand Turicibacter in intestinal floras of the rats can be recovered; simulated gastrointestinal fluid can be tolerated, the bifidobacterium adolescentis can be quickly colonized in intestinal tracts,accordingly, rat livers with metabolic syndromes, pathological injury of duodenums and increase of the contents of triglyceride and total cholesterol in serum due to the high-glucose and high-fat dietand oral glucose tolerance can be remarkably improved, and the bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder such as the metabolic syndromes, irritable bowel syndromes and psychological illnesses such as anxiety and depression which are related to the metabolic syndromes.

A composition is provided which contains policosanol and HMG-Co-A reductase inhibitor and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis immunoregulatory diseases, cardiovascular diseases, and / or neurodegenerative disorders in humans and animals. The method comprises administering policosanol and HMG-Co-A reductase inhibitor which together effectively lower serum cholesterol levels. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to HMG-Co-A reductase inhibitor.

A health monitoring and diagnostic device (LIFESTREAM cholesterol meter) configured as a self-contained testing and diagnostic unit in a clam-shell type case. One side of the case includes a spring-loaded finger stick and a compartment for carrying one or more packages of disposable items including a test strip, a needle for the finger stick, and an alcohol swipe. The other half of the case includes a test strip reader, a key pad, and a liquid crystal display. The meter reads a test strip carrying a droplet of blood and receives additional diagnostic information from the patient, such as age, gender, weight, and family history of heart disease. Within minutes, the meter displays test results, including total cholesterol levels. The meter also displays additional diagnostic results, such as the patient's “cardiac age,” recommended weight loss, and a cardiac risk assessment. The meter also works in connection with a network-based comprehensive health analysis and reporting system. The meter writes patient data to a smartcard. This patient data typically includes patient identification information, the test results, the diagnostic information, and the diagnostic results. A computer station reads the smartcard and establishes a network connection with a health report server over the Internet. The computer then downloads the patient data to the health report server, which prepares a comprehensive health report. Within minutes, this report is transmitted back to the computer station, where it is printed out and delivered to the patient.

A method and system for treating non-alcoholic fatty liver disease (NAFLD) involves the modulation of the gut microbial of a person suffering from NAFLD, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, TNF-α and to improve insulin resistance in NAFLD patients.

A health monitoring and diagnostic device (LIFESTREAM cholesterol meter) configured as a self-contained testing and diagnostic unit in a clam-shell type case. One side of the case includes a spring-loaded finger stick and a compartment for carrying one or more packages of disposable items including a test strip, a needle for the finger stick, and an alcohol swipe. The other half of the case includes a test strip reader, a key pad, and a liquid crystal display. The meter reads a test strip carrying a droplet of blood and receives additional diagnostic information from the patient, such as age, gender, weight, and family history of heart disease. Within minutes, the meter displays test results, including total cholesterol levels. The meter also displays additional diagnostic results, such as the patient's “cardiac age,” recommended weight loss, and a cardiac risk assessment. The meter also works in connection with a network-based comprehensive health analysis and reporting system. The meter writes patient data to a smartcard. This patient data typically includes patient identification information, the test results, the diagnostic information, and the diagnostic results. A computer station reads the smartcard and establishes a network connection with a health report server over the Internet. The computer then downloads the patient data to the health report server, which prepares a comprehensive health report. Within minutes, this report is transmitted back to the computer station, where it is printed out and delivered to the patient.

A multilayer test strip that measures concentrations of multiple analytes from a single whole blood sample. The test strip includes a test matrix of several layers held together in constant contact by a test strip holder. The invention is characterized in that it has no moving parts, which is made possible by the novel use of an elongate disbursement layer that spreads blood throughout its entire length, despite having layers with known wicking properties adjacent to and in contact with it. Since the invention relies primarily on a vertical flow format, the test strip is advantageously quite compact. With a single 35 microliter sample of blood applied thereto, the novel test strip can provide readings of total cholesterol, HDL cholesterol and triglycerides. From these, LDL can be calculated, thereby providing a full “lipid panel.” Other analytes such as glucose and ketones may be included in the test strip in addition to or in lieu of one or more of the other analytes.

Methods of treating high serum levels of total cholesterol, low density lipoprotein and triglycerides in a mammal by administering therapeutically effective doses of N-(4-{[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]amino}phenyl)acetamide or a salt thereof such as a hydrochloride or hydrobromide salt.

The invention provides a method for lowering circulating LDL-cholesterol or total cholesterol in a human in need thereof, comprising: orally administering to the human a therapeutically effective amount of a statin and vitamin D daily for at least about 6 weeks, wherein the vitamin D is administered by one or more pharmaceutical compositions.

The invention relates to the technical field of a medicine, provides a mussel polysaccharide MA separated from common mussel and a preparation method thereof. Proven through blood fat lowering test in animal bodies, the mussel polysaccharide MA is significant in treating white rat hyperlipemia induced by high-fat feedstuff, and can reduce the level of total cholesterol, triglyceride and low density lipoprotein in white rates. The action of the mussel polysaccharide MA is equal to the action of pravastatin as a positive medicine or Xuezhikang. Accordingly, the mussel polysaccharide MA can be applied for preparing medicines or food for lowering blood fat, which is of far reaching importance for making the most of living marine resources.

The invention provides Chinese herbal medicine additive for improving meat quality of java tilapia, containing by weight of: 22-30% of spatholobus stem, 30-40% of black bean, 10-15% of glycyrrhiza, 5-10% of honeysuckle, 5-10% of radix isatidis and 10-15% of hawthorn. The advantages of the invention comprise: (1) having good phagostimulant effect, (2) substantially reducing fat content and cholesterol level in muscles of java tilapia, substantially increasing flavor substance content of inosinic acid in muscles, improving muscles quality of java tilapia, (3), adding and using conveniently, and directly adding in commercial feedstuff, wherein the components can generates synergistic effect with other additive components in commercial feedstuff, and raise weighting rate and disease resistance of java tilapia, and (4) having stabile raw material resource, low price, simple production process and easy for industrialization production.

The invention relates to a probiotic composition, and discloses a probiotic composition beneficial for a glycolipid metabolic function and a preparation and application of the composition. The probiotic composition comprises some of the following nine probiotics: bifidobacterium longum, bifidobacterium breve, lactobacillus gasseri, lactobacillus rhamnosus, lactobacillus salivarius, lactobacillus crispatus, lactobacillus plantarum, lactobacillus fermentum and lactobacillus casei. Different strains in the probiotic composition cooperate with each other, so that the probiotic composition has thefunction of adjusting glycolipid metabolism, and has certain effect on serum total cholesterol, triglycerides, insulin beta-cell functions and diabetes mellitus improvement.

The ketogenic diet (KD) has therapeutic implications in many disease states. It was hypothesized ketone precursor supplementation would elevate blood ketone levels to therapeutic ranges (2-7 mM) without need for dietary restriction. The effects of ketogenic agents were tested on blood glucose, ketones, and lipids with a 28-day dose escalation study in male Sprague-Dawley rats: R,S-1,3-Butandiol (BD), acetoacetate ketone ester (KE), and control (H2O) (n≧8). Days 1-28, rats received a daily 5 g / kg intragastric gavage, based on previous toxicology studies. Once weekly, whole blood samples (10 μl) were acquired for analysis of glucose and βHB at 0, 0.5, 1, 4, 8, and 12 hours after test substance administration, or until βHB returned to baseline. At day 1 and 28, 10 μL of whole blood were collected to measure triglycerides, total cholesterol, and HDL concentration. Significant elevation of blood ketone was observed with a significant inverse relationship with blood glucose for the duration of the experiment. There were no significant changes in the lipid panel for any of the substances. There were significant reductions in body weight when animals were treated with either BD or KE as compared to control.

The invention provides a production technology of a blood lipid reducing lotus leaf tea, pertaining to the tea processing technical field. Fresh lotus leaves are cut into squares with a side length of 4cm, laid open on a conveyer belt of a 6CW-10E type tea microwave de-enzyming and drying device for being treated with de-enzyming of the lotus leaves, laid for cooling for 20min, put into a 6CR-30 type tea roller for rolling for 20-40min based on a principle of 'light-heavy-light', then the lotus leaves are laid open on the conveyer belt evenly for drying and cooling, crushed through 40 meshes and packaged into tea bags. The production process of the lotus tea provided by the invention adopts microwave technology for de-enzyming and drying the lotus leaves, which greatly shortens the production time of the lotus leaf tea, improves the production efficiency and enhances preservation of flavone substances in the lotus leaves. Water soluble lotus leaf flavone contained in the tea soup of the lotus leaf tea is not less than 0.23mg / g, thereby being capable of reducing serum triglyceride and total cholesterol remarkably and having auxiliary function for reducing blood lipid.

The invention features bioactive compounds obtainable from goldenseal and methods of use of such compounds in reducing lipid (at least one of total cholesterol, LDL-cholesterol, free fatty acids, or triglycerides) in a patient having or suspected of having hyperlipidemia.

There is provided a therapy for lowering the blood levels of a lipid selected from the group comprising LDL cholesterol, triglycerides, overall cholesterol and mixtures thereof, the therapy comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.

The invention relates to a preparation method of an adsorbent for adsorbing low-density lipoprotein (LDL) for whole blood perfusion. The preparation method comprises the following steps: performing chloromethylation modification and hydroxylation modification on polystyrene adsorption resin, then performing epichlorohydrin activation to ensure that the surface of the polystyrene macroporous adsorption resin carries a great quantity of active groups, and further immobilizing polyanion ligands onto the polystyrene macroporous adsorption resin. The whole blood perfusion adsorbent with excellent adsorption performance on LDL, TG (triglyceride) and TC (total cholesterol) is prepared by combining the electronegativity of polyanion, the hydrophobicity of a polystyrene resin skeleton structure and the pore adsorption action of the macroporous adsorption resin.

The invention discloses a making method of chickpea natto. The method comprises the following steps of: soaking the chickpea for sprouting, steaming and boiling, inoculating, fermenting, after-ripening, freeze-drying and the like. In the method, the chickpea biochanin isoflavone is generated by carrying out the sprouting pretreatment on the chickpea; the nutritional ingredients of the chickpea are enhanced; and subsequently the natto bacillus subtilis is inoculated for fermentation so as to make the chickpea natto which is rich in chickpea flavonoid, bacillus natto and nattokinase. In addition, the invention also discloses the chickpea natto made by using the method and the application of the chickpea natto for preparing health-care foods or medicines for preventing or improving hyperlipidemia and resisting thrombosis. The experiments show that the chickpea natto disclosed by the invention can reduce the contents of the TC (total cholesterol), the TG (total glycerin) and the MAD (monoamine oxidase) of the organism blood serum, has the significant blood-fat depression and thrombolytic functions, and can be used for preparing the health-care foods or medicines for preventing or improving hyperlipidemia and resisting thrombosis.

The invention discloses a large data cardiovascular disease risk monitoring system. According to the system, personal information (including age, sex, blood pressure, height, weight, obesity index and the like) of health examinations, physical examinations and hospital treatment, and test data of blood routine, blood biochemistry and myocardial enzymes are used for monitoring the cardiovascular disease risk. The invention belongs to the application of large data in the field of health care, and further belongs to the crossing technical field of large data and health care. The invention aims at providing a simple, easy, practical and accurate cardiovascular risk monitoring system. The current monitoring of the cardiovascular disease risk is achieved mostly by enquiring a small sample amount of data collected by a questionnaire method such as disease history, family history and major risk factors for the cardiovascular disease and through the data of blood sugar collected by an instrument, total cholesterol and the like. The monitoring is controlled and managed by medical institutions and doctors so that users can not carry out the monitoring of the cardiovascular disease risk by themselves. Due to the fact that epidemiological features of a cardiovascular disease spectrum and risk factors in Chinese population are significantly different from the epidemiological features in western developed countries. The existing risk assessment tools in Europe and America are not suitable for the Chinese population. With the help of a large data value extraction technology, the large data cardiovascular disease risk monitoring system can monitor the cardiovascular disease risk for users and doctors and provide hope for human to monitor the cardiovascular disease risk by themselves and conquer the cardiovascular disease.

In one aspect, the present invention features HCV therapies comprising administering to a patient in need thereof an HCV protease inhibitor and ritonavir, wherein ritonavir is used as a pharmacokinetic booster to improve the pharmacokinetics of the HCV protease inhibitor. The HCV therapies do not require the testing of total cholesterol and triglyceride levels prior to and after the therapies.

The present invention relates to a fermented coconut milk drink and a preparation method thereof, the fermented coconut milk drink is prepared from coconut milk, syrup or a sugar substitute, and pure water as raw materials for fermentation by selected plant lactobacillus, the fermented coconut milk drink is prepared by the method is unique in flavor, nutrient-rich, and smooth and fresh in taste, the short chain fatty acid level of the fermented coconut milk drink is significantly improved after fermentation by the plant lactobacillus, and the fermented coconut milk drink can significantly reduce total cholesterol (TC) and triglyceride (TG) content in fasting blood-glucose and blood fat of hyperlipemia rats, and has significant health benefits.

The present invention relates to a sampling device for taking up a blood sample and for providing the blood sample for analysis of total cholesterol in said blood sample. The device comprises a receiving cavity for receiving, through capillary action, the blood sample to be analysed, said receiving cavity having a predetermined small volume; and an analysis cavity, arranged in communication with the receiving cavity, said analysis cavity having a predetermined optical path length. The receiving cavity contains a dried buffer, and the analysis cavity contains a dried reagent. The invention also relates to a method for quantitative determination of the total cholesterol concentration in a blood sample of serum / plasma by end point analysis.

The invention relates to a health-care food composite with a function of assisting in reducing blood fat and a preparation method thereof. According to the invention, 100-200 parts by weight of freeze-dried natto powder, 100-200 parts by weight of red yeast, 100-220 parts by weight of phytosterol and clinically acceptable auxiliary materials are prepared into hard capsules, tablets, granules and powder. According to the invention, a complementary concept is adopted, and through the combination of three kinds of raw materials, the serum total cholesterol can be effectively reduced, and the triglyceride can be reduced, therefore, the health-care food composite has a health-care function of assisting in reducing blood fat; and in each 100g of the health-care food composite, the weight of the efficacy component phytosterol is higher than 10 g, and the weight of lovastatin is higher than 0.1 g.

Shilajit in a standardized composition produces a significant improvement in several cardiovascular parameters including RI, AIx and SEVR. Further, significant reductions in malondialdehyde and increases in nitric oxide levels are provided suggesting improvement in endothelial function. Shilajit may be used to reduce inflammatory biomarker HsCRP levels significantly compared to baseline and placebo. Additionally, Shilajit can provide significant improvement in lipid parameters including total cholesterol, LDL-C, and HbA1c (%) Inhibition of platelet aggregation using Shilajit performed using ADP as aggregant also provides highly significant inhibition of platelet aggregation compared to baseline and with placebo. Thus, Shilajit may be used for improvement of endothelial function and to help reduce cardiovascular morbidity, particularly for the diabetic individual.

The invention provides a planting method of underwood grassland for breeding chickens, which pertains to the agricultural technical field. The method comprises the following steps: firstly, a forest land with a canopy density less than 70 percent is selected; secondly, purple alfalfa and chicory are sowed in a mixed way according to a percentage by seed weight of 30 to 60 percent and 70 to 40 percent, namely, each kilogram of mixed sowing seeds contains 0.3 to 0.6kg of purple alfalfa seeds and 0.7 to 0.4kg of chicory seeds, the sowing rate is 1.5 to 3.0 kg / mu (mu: a Chinese unit of area, 1 / 15 of a hectare), thereby forming an underwood grassland for breeding chickens, which can improve the immunizing ability of the chickens but reduce the total cholesterol content in the chickens. Breeding and utilizing the grassland start when the purple alfalfa and the chicory planted on the grassland grow to an average height of 15cm. The underwood grassland of the invention is characterized by improving the immunizing ability of the chickens, reducing the total cholesterol content of the chickens, saving feed, promoting the economic benefit of ecological forests and economic forests and producing high quality chickens.

The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.

The invention belongs to the field of traditional Chinese medicines and relates to a use of rhizoma smilacis glabrae extract in preparation of lipid-lowering and fat-reducing medicines and health-care foods. The rhizoma smilacis glabrae extract comprises 5-O-caffeoylshikimic acid, astilbin, isoastilbin, neoastilbin, neoisoastilbin, taxifolin, engeletin, isoengelitin and resveratrol. An animal experiment shows that the rhizoma smilacis glabrae extract can obviously reduce mice abdominal cavity fat weight, reduce mice body weight, and reduce triglyceride and total cholesterol concentrations of mice serum. Effects of the rhizoma smilacis glabrae extract are stronger than effects of a single astilbin component. The rhizoma smilacis glabrae extract is extracted from traditional Chinese medicines, has synergism of components, has good fat-reducing effects and broadens a rhizoma smilacis glabrae application range.